Emerging treatment options for patients with Laron syndrome

Expert Opinion on Orphan Drugs

Volumn 2, Issue 7, 2014, Pages 681-694

  Laron, Zvi ^a  

^a SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

Author keywords

Adverse effect to IGF I; Growth hormone insensitivity; Growth hormone receptor gene mutations and deletions; IGF I treatment of Laron syndrome; Laron syndrome

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM; GROWTH HORMONE RELEASING FACTOR; HEMOGLOBIN A1C; HUMAN GROWTH HORMONE; INSULIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MECASERMIN RINFABATE; PHOSPHORUS; POTASSIUM; PROLACTIN; RECOMBINANT HUMAN INSULIN LIKE GROWTH FACTOR 1; RECOMBINANT SOMATOMEDIN C; THYROTROPIN; UNCLASSIFIED DRUG;

ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BRAIN GROWTH; CALCIUM URINE LEVEL; COUNSELING; DIETARY INTAKE; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DWARFISM; EARLY DIAGNOSIS; ERYTHROPOIESIS; HOMOZYGOTE; HORMONE DEFICIENCY; HUMAN; HYPERANDROGENISM; HYPOGLYCEMIA; INJECTION SITE PAIN; INTRACRANIAL HYPERTENSION; LARON SYNDROME; LIPOHYPERTROPHY; NONALCOHOLIC FATTY LIVER; OBESITY; PAPILLEDEMA; PRENATAL CARE; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REVIEW; SLEEP DISORDERED BREATHING; SNORING; SOFT TISSUE DISEASE; ST SEGMENT DEPRESSION; SWELLING; T WAVE; TACHYCARDIA; TREATMENT DURATION;

EID: 84903317864     PISSN: None     EISSN: 21678707     Source Type: Journal    
DOI: 10.1517/21678707.2014.912581     Document Type: Review

References (136)

1. Laron Z, Pertzelan A, Mannheimer S. Genetic pituitary dwarfism with high serum concentration of growth hormone. A new inborn error of metabolism?. Isr J Med Sci 1966;2:153-5
2. Laron Z, Pertzelan A, Karp M. Pituitary dwarfism with high serum levels of growth hormone. Isr J Med Sci 1968;4:883-94
3. Laron Z. Laron type dwarfism (hereditary somatomedin Deficiency): A review. In: Frick P, Von Harnack GA, Kochsiek GA, Prader A, editors. Adv Int Med Pediat. Springer-Verlag, Berlin-Heidelberg; 1984. p. 51:117-50
4. Laron Z. Laron syndrome (primary growth hormone resistance on insensitivity): The personal experience 1958-2003. J Clin Endocrinol Metab 2004;89:1031-44
5. Laron Z, Kopchick JJ. editors. Laron syndrome-from man to mouse. Springer-Verlag, Heidelberg, New York; 2011. p. 531
6. Keret R, Pertzelan A, Zeharia A, et al. Growth hormone (hGH) secretion and turnover in three patients with Larontype dwarfism. Isr J Med Sci 1988;34:75-9
7. Laron Z, Efros O. Lifelong serum growth hormone levels in patients with Laron syndrome. In: Laron Z, Kopchick JJ, editors. Laron syndrome from man to mouse. Springer-Verlag; Heidelberg, New York; 2011. p. 235-9
8. Daughaday WH, Laron Z, Pertzelan A, et al. Defective sulfation factor generation: A possible etiological link in Dwarfism. Trans Assoc Am Physicians 1969;82:129-38
9. Laron Z, Pertzelan A, Karp M, et al. Administration of growth hormone to patients with familial dwarfism with high plasma immunoreactive growth hormone. Measurement of sulfation factor, metabolic and linear growth responses. J Clin Endocrinol Metab 1971;33:332-42
10. Laron Z. Diagnosis of Laron syndrome. In: Laron Z, Kopchick JJ, editors. Laron syndrome-from man to mouse. Springer-Verlag; Heidelberg, New York; 2011. p. 27-8
11. Eshet R, Laron Z, Brown M, et al. Immunoreactive properties of the plasma hGH from patients with the syndrome of familial dwarfism and high plasma IR-hGH. J Clin Endocrinol Metab 1973;37:819-21
12. Eshet R, Laron Z, Brown M, et al. Immunological behavior of hGH from plasma of patients with familial dwarfism and high IR-hGH in a radioimmunoassay system using the cross-reaction between hGH and HCS. Horm Metab Res 1974;6:80-1
13. Russell RE, Parks JS, McKean MC, et al. Laron-Type dwarfism is associated with normal growth hormone and insulin-like growth factor I gene restriction patterns. Isr J Med Sci 1989;25:342-4
14. Laron Z, Kowadlo-Silbergeld A, Eshet R. Growth Hormone Resistance. Ann Clin Res 1980;12:269-77
15. Eshet R, Laron Z, Pertzelan A, et al. Defect of human growth hormone in the liver of two patients with Laron type dwarfism. Isr J Med Sci 1984;20:8-11 (Pubitemid 14167010
16. Geffner ME, Golde DW, Lippe BM, et al. Tissues of the Laron Dwarf are sensitive to insulin-like growth factor I but not to growth hormone. J Clin Endocrinol Metab 1987;64:1042-6 (Pubitemid 17067441
17. Godowski PJ, Leung DW, Meacham LR, et al. Characterization of the human growth hormone receptor gene and demonstration of a partial gene deletion in two patients with Laron type dwarfism. Proc Natl Acad Sci USA 1989;86:8083-7 (Pubitemid 19265324
18. Amselem S, Duquesnoy P, Attree O, et al. Laron Dwarfism and mutations of the growth hormone-receptor gene. N Engl J Med 1989;321:989-95 (Pubitemid 19253412
19. Rosenfeld RG, Rosenbloom AL, Guevara-Aguirre J. Growth hormone (GH) insensitivity due to primary GH receptor deficiency. Endocr Rev 1994;15:369-90 (Pubitemid 24180794
20. Rosenbloom AL, Guevara-Aguirre J. Growth hormone receptor deficiency in South America: CXolonial history, molecular biology, and growth and metabolic insights. J Pediatr Endocrinol Metab 2008;21:1107-19
21. Savage MO, Attie KM, David A, et al. Endocrine, molecular characterization and treatment of growth hormone insensitivity disorders. Nat Clin Pract Edocrinol Metab 2006;2:395-407 (Pubitemid 44050109
22. Shevah O, Laron Z. Genetic analysis of the pedigrees and molecular defects of the GH-receptor gene in the Israeli cohort of patients with Laron syndrome. Pediatr Endocrinol Rev 2006;3(Suppl 3):489-97. Erratum in: Pediatr Endocrinol Rev. 2007;5:470
23. Shevah O, Laron Z. Genetic aspects. In: Laron Z, Kopchick JJ, editors. Laron syndrome-from man to mouse. Springer; Heidelberg, New York; 2011. p. 29-48
24. David A, Hwa V, Metherell LA, et al Evidence for a continuum of genetic, phenotypic, and biochemical abnormalities in children with growth hormone insensitivity. Endocr Rev 2011;32:472-97
25. Niwa M, Sato Y, Uchiyama F, et al. Chemical synthesis, cloning and expression of genes for human somatomedin C (insulin like growth factor I) and 5aval somatomedin C. Ann NY Acad Sci 1986;469:31-52 (Pubitemid 16000190
26. Rinderknecht E, Humbel RE. The amino acid sequence of human insulin like growth factor I and its structural homology with proinsulin. J Biol Chem 1978;253:2769-76 (Pubitemid 8326483
27. Blundell TL, Humbel RE. Hormone families: Pancreatic hormones and homologous growth factors. Nature 1980;287:781-7 (Pubitemid 11214474
28. Laron Z. Somatomedin-I (recombinant insulin-like growth factor-I). Clinical pharmacology and potential treatment of endocrine and metabolic disorders. BioDrugs 1999;11:55-70
29. Jones JI, Clemmos DR. Insulin-like growth factors and their binding proteins: Biological actions. Endocr Rev 1995;16:3-34
30. Bach LA, Rechler MM. Insulin-like growth factor binding proteins. Diabetes Rev 1995;3:38-61
31. Zapl J. Physiological role of the insulinlike growth factor binding proteins. Euro J Endocrinol 1995;132:645-54
32. McCusker RH, Clemmons DR. The insulin-like growth factor binding proteins: Structure and biological functions. In: Schofield PN, editor. The insulin-like growth factors: Structure and biological functions. Oxford University Press, New York; 1992. p. 110-50
33. Baxter RC. Circulating binding proteins for the insulin-like growth factors. Trends Endocrinol Metab 1993;4:91-6 (Pubitemid 23144186
34. Silbergeld A, Litwin A, Bruchis S, et al. Insulin-like growth factor (IGF-I) in healthy children, adolescents and adults as determined by a radioimmunoassay specific for the synthetic 53-70 peptide region. Clin Endocrinol (Oxf) 1986;25:67-74 (Pubitemid 16057665
35. Guler HP, Zapf J, Schmid C, et al. Insulin-like growth factors I and II in healthy man. Estimations of half lives and production rates. Acta Endocrinol 1989;121:753-8
36. Laron Z, Pertzelan A, Doron M, et al. The effect of dihydrosomatostatin in Dwarfism with high plasma immunoreactive growth hormone. Horm Metab Res 1977;9:338-9 (Pubitemid 8161462
37. Klinger B, Garty M, Laron Z. Elimination characteristics of intravenously administered rIGF-I in Laron-Type dwarfs. Dev Pharmacol Ther 1990;15:196-9
38. Laron Z, Klinger B, Blum WF, et al. IGF binding protein 3 in patients with LTD: Effect of exogenous rIGF-I. Clin Endocrinol (Oxf) 1992;36:301-4
39. Grahnen A, Kastrup K, Heinrich U, et al. Pharmacokinetics of recombinant human insulin-like growth factor I given subcutaneously to healthy volunteers and to patients with hormone receptor deficiency. Acta Paediatr 1993;391(Suppl):7-13
40. Laron Z, Klinger B, Erster B, et al. Effect of acute administration of insulinlike growth factor I in patients with Laron-Type dwarfism. Lancet 1988;2:1170-2 (Pubitemid 18267007
41. Laron Z, Klinger B, Silbergeld A, et al. Intravenous administration of recombinant IGF-I lowers serum GHRH and TSH. Acta Endocrinol (Copenh) 1990;123:378-82 (Pubitemid 20340330
42. Walker JL, Ginalska-Malinowska M, Romer TE, et al. Effects of the infusion of insulin like growth factor I in a child with growth hormone insensitivity syndrome (Laron Dwarfism). N Engl J Med 1991;324:1483-8
43. Laron Z, Klinger B, Jensen LT, et al. Biochemical and hormonal changes induced by one week of administration of rIGF-I to patients with Laron type dwarfism. Clin Endocrinol (Oxf) 1991;35:145-50
44. Silbergeld A, Klinger B, Schwartz H, et al. Serum prolactin in patients with Laron type dwarfism: Effect on insulin like growth factor 1. Horm Res 1992;37:160-4 (Pubitemid 23027408
45. Laron Z, Klinger B. Effect of insulin-like growth factor-I treatment on serum androgens and testicular and penile size in males with Laron syndrome (primary growth hormone resistance). Eur J Endocrinol 1998;138:176-80 (Pubitemid 28131095
46. Gafny M, Silbergeld A, Klinger B, et al. Comparative effects of GH, IGF-I and insulin on sex hormone binding globulin. Clin Endocrinol (Oxf) 1994;41:169-75
47. Vaccarello MA, Diamond FB, Guevara-Aguirre J Jr, et al. Hormonal and metabolic effects and pharmacokinetics of recombinant insulinlike growth factor-I in growth hormone receptor deficiency/Laron syndrome. J Clin Endocrinol Metab 1993;77(1):273-80 (Pubitemid 23206815
48. Kanety H, Karasik A, Klinger B, et al. Long-Term treatment of Laron type dwarfs with insulin-like growth factor I increases serum insulin-like growth factor-binding protein 3 in the absence of growth hormone activity. Acta Endocrinol 1993;128:144-9 (Pubitemid 23073934
49. Kanety H, Silbergeld A, Klinger B, et al. Long-Term effects of insulin-like growth factor-I (IGF-I) on serum IGF-I, IGF binding protein 3 (IGFBP3) and acid labile subunit in Laron syndrome patients with normal GHBP. Eur J Endocrinol 1997;137:626-30 (Pubitemid 28005255
50. Laron Z, Klinger B, Blum WF, et al. IGF binding protein 3 in patients with LTD: Effect of exogenous rIGF-I. Clin Endocrinol (Oxf) 1992;36:301-4
51. Laron Z, Anin S, Klipper-Aurbach Y, et al. Effects of insulin-like growth factor on linear growth, head circumference, and body fat in patients with Laron-Type dwarfism. Lancet 1992;339:1258-62
52. Walker JL, Van Wyk JJ, Underwood LE. Stimulation of statural growth by recombinant insulin-like growth factor I in a child with growth hormone insensitivity syndrome (Laron type). J Pediatr 1992;10:641-6
53. Wilton P; on behalf of the Kabi Pharmacia Study Group on Insulin-Like Growth Factor I Treatment in Growth Hormone Insensitivity Syndromes. Treatment with recombinant human insulin-like growth factor I of children with growth hormone receptor deficiency (Laron syndrome). Acta Paediatr Suppl 1992;383:137-41
54. Laron Z. One-year treatment with IGF-I of children with Laron syndrome. Clin Courier 1993;11:7-8
55. Heinrichs C, Vis HL, Bergmann P, et al. Effects of 17 months treatment using recombinant insulin-like growth factor-I in two children with growth hormone insensitivity (Laron) syndrome. Clin Endocrinol (Oxf) 1993;38:647-51 (Pubitemid 23168482
56. Martinez V, Vasconez O, Martinez AL, et al. Body changes in adolescent patients with growth hormone receptor deficiency receiving recombinant human insulin-like growth factor I and luteinizing hormonereleasing hormone analogue: Preliminary results. Acta Paediatr Suppl 1994;399:133-6 (Pubitemid 24261898
57. Ranke MB, Savage MO, Chatelain PG, et al. Insulin-like growth factor I improves height in growth hormone insensitivity: Two years' results. Horm Res 1995;44:253-64 (Pubitemid 26027275
58. Guevara-Aguirre J, Rosenbloom AL, Vasconez O, et al. Two-year treatment of growth hormone (GH) receptor deficiency with recombinant insulin-like growth factor I in 22 children: CXomparison of two dosage levels and to GH deficiency. J Clin Endocrin Metab 1997;82(2):629-33 (Pubitemid 27068641
59. Azcona C, Preece MA, Rose J, et al. Growth response to rhIGF-I 80 μg/kg twice daily in children with growth hormone insensitivity syndrome: Relationship to severity of clinical phenotype. Clin Endocrin (Oxf) 1999;51:787-92 (Pubitemid 30050830
60. Walker JL, Crock PA, Behnchken SN, et al. A novel mutation affecting the interdomain link region of the growth hormone receptor in a Vietnamese girl, and response to long-Term treatment with recombinant human insulin-like growth factor-I and luteinizing hormonereleasing hormone analogue. J Clin Endocrinol Metab 1998;83:2554-61 (Pubitemid 28503061
61. Besson A, Salemi S, Eblé A, et al. Primary GH insensitivity (Laron syndrome) caused by a novel 4kb deletion encompassing exon 5 of the GH receptor gene: Effect of intermittent longterm treatment with recombinant human IGF-I. Europ J Endocrinol 2004;150:635-42 (Pubitemid 38786532
62. Kržiŝnik V, Battelino T. Five year treatment with IGF-I of a patient with Laron syndrome in Slovenia. J Pediat Endocrinol Metab 1997;10:443-7
63. Zucchini S, Scarano E, Baldazzi L, et al. Final height in a patient with Laron syndrome after long-Term therapy with rhIGF-I and short-Term therapy with LHRG-Analogue and oxandrolone during puberty. J Endocrinol Invest 2005;28:274-9 (Pubitemid 43162777
64. Kaji H, Nose O, Tajiri H, et al. Novel compound heterozygous mutation of growth hormone (GH) receptor gene in a patient with GH insensitivity syndrome. J Clin Endocrinol Metab 1997;82:3705-9 (Pubitemid 27509359
65. Ranke MB, Savage MO, Chatelain PG, et al. Long-Term treatment of growth hormone insensitivity syndrome with IGF-I. Results of the European Multicentre Study. Horm Res 1999;51:128-34
66. Backeljaw P F, Underwood LE; and the GHIS Collaborative Group. Prolonged treatment with recombinant insulin-like growth factor-I in children with growth hormone insensitivity syndrome - A clinical research center study. J Clin Endocrinol Metab 1996;81:3312-17
67. Backeljaw PF, Underwood LE; and the GHIS Collaborative Group. Therapy for 6.5-7.5 years with recombinant insulinlike growth factor I in children with growth hormone insensitivity syndrome: A clinical research center study. J Clin Endocrinol Metab 2001;86:1504-10
68. Chernausek SD, Backeljauw PF, Frane J, et al. Long-Term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity. J Clin Endocrinol Metab 2007;92:902-10 (Pubitemid 46465661
69. Backeljaw PF, Chernausek SD. The insulin-like growth factors and growth disorders of childhood. Endocrinol Metab Clin North Am 2012;41:265-82
70. Backeljaw Ph F, Kuntze J, Frane J, et al. Adult and near-Adult height in patients with severe insulin-like growth factor-I deficiency after long-Term therapy with recombinant human insulin-like growth factor-I. Horm Res Paediatr 2013;80:47-56
71. Underwood L, Chernausek SD, Kuntze J, et al. Efficacy of Long-Term treatment with recombinant human IGF-I (rhlGF-I) of children with GH insensitivity [abstract P3-451. 86th Annual Meeting of the Endocrine Society; New Orleans, LA, USA; 2004. 575
72. Frane J, Bailly J, Chernausek S, et al. Growth responses to higher dose recombinant human IGF-I (rhIGF-I) in children with severe primary IGF-I deficiency (IGFD) due to growth hormone insensitivity (GHIS) [abstract P03-619. Horm Res 2006;65(Suppl 4):180
73. Klinger B, Laron Z. Three year IGF-I treatment of children with Laron syndrome. J Clin Endocrinol Metab 1995;8:149-58
74. Laron Z. Insulin-like growth factor-I treatment of children with laron syndrome (primary growth hormone insensitivity). Pediatr Endocrinol Rev 2008;5(3):766-71 (Pubitemid 351462140
75. Laron Z. IGF-I treatment of patients with Laron syndrome. In: Laron Z, Kopchick JJ, editors. Laron syndrome from man to mouse. Springer, Heidlberg, New York; 2011. p. 343-80
76. Laron Z, Ginsberg S, Lilos P, et al. Long-Term IGF-I treatment of children with Laron syndrome increases adiposity. Growth Horm IGF Res 2006;16:61-4 (Pubitemid 43205316
77. Laron Z. Effects of long-Term administration of IGF-I on the adipose tissue and carbohydrate metabolism in children with Laron syndrome. In: Laron Z, Kopchick JJ, editors. Laron syndrome from man to mouse. Springer, Heidlberg, New York; 2011. p. 389-408
78. Laron Z, Silbergeld A, Kauli R. Differential effects of hGH and IGF-I on body proportions. Anthropol Anz (J Biol Clinic Anthrop) 2012;69:255-9
79. Laron Z. If one daily injection of IGF-I has the same growth promoting effect as 2 injections a day why continue to give two injections?. Pediatr. Encocrinol Rev 2013;10:277-9
80. Ranke MB. Clinical considerations in using growth hormone therapy in growth hormone deficiency. In: Hindmarsh PC, editor. Current indications for growth hormone therapy. Revised 2nd edition. Endocr Dev Basel, Karger; Basel; 2010. p. 18:83-91
81. Green H, Morikawa M, Nixton T. A dual effector theory of growth hormone action. Differentiation 1985;29:195-8 (Pubitemid 16252644
82. Liu J-L, LeRoith D. Insulin-like growth factor I is essential for postnatal growth in response to growth hormone. Endocrinology 1999;140:5178-84
83. Laron Z, Iluz M, Kauli R. Head circumference in untreated and IGF-I treated patients with Laron syndrome Comparison with untreated and hGHtreated children with isolated growth hormone deficiency. Growth Horm IGF Res 2012;22:49-52
84. Konen O, Silbergeld A, Lilos P, et al. Hand size and growth in untreated and IGF-I treated patients with Laron syndrome. Pediatr Nephrol 1994;8:684-8
85. Silbergeld A, Lilos P, Laron Z. Foot length before and during insulin-like growth factor-I treatment of children with Laron syndrome compared to human growth hormone treatment of children with isolated growth hormone deficiency. J Pediatr Endocrinol Metab 2007;20:1325-8
86. Klinger B, Laron Z. Renal function in Laron syndrome patients treated by insulin-like growth factor-I. Pediatr Nephrol 1994;8:684-8
87. Sivan B, Lilos P, Laron Z. Effects of insulin-like growth factor-I deficiency and replacement therapy on the hematopoietic system in patients with Laron syndrome (primary growth hormone insensitivity). J Pediatr Endocrinol Metab 2003;16:509-20 (Pubitemid 37259139
88. Attias J, Zarchi O, Nageris BI, et al. Cochlear hearing loss in patients with Laron syndrome. Eur Arch Otorhinolaryngol 2012;269:461-6
89. Laron Z, Wang XL, Klinger B, et al. Insulin-like growth factor-I decreases serum lipoprotein (a) during long-Term treatment of patients with Laron syndrome. Metabolism 1996;45(10):1263-6 (Pubitemid 26337673
90. Laron Z, Klinger B. IGF-I treatment of adult patients with Laron syndrome: Preliminary results. Clin Endocrinol (Oxf) 1994;41(5):631-8 (Pubitemid 24336866
91. Klinger B, Jensen LT, Silbergeld A, et al. Insulin-like growth faction -I raises serum procollagen levels in children and adults with Laron syndrome. Clin Endocrinol (Oxf) 1996;45:423-9 (Pubitemid 26383419
92. Ben-Amitai D, Laron Z. Effect of insulin-like growth factor-I deficiency or administration on the occurrence of microcomedones and acne. J Eur Acad Dermatol Venereol 2011;25:950-4
93. Mauras N, Martinez V, Rini A, et al. Recombinant human insulin-like growth factor I have significant anabolic effects in adults with growth hormone receptor deficiency: Studies on protein, glucose, and lipid metabolism. J Clin Endocrinol Metab 2000;85(1):3036-42
94. Feinberg MS, Scheinowitz M, Laron Z. Echocardiographic dimensions and function in adults with primary growth hormone resistance (Laron syndrome). Am J Cardiol 2000;85:209-13 (Pubitemid 30026104
95. Norman P. SomatoKine, Insmed. Curr Opin Investig Drugs 2003;4:466-71
96. Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 2002;23:824-54 (Pubitemid 35454590
97. Camacho-Hübner C, Storr HI, Miraki-Moud F, et al. Pharmacokinetic studies of rhIGF-I/rhIGFBP-3 complex administered to patients with growth hormone insensitivity syndrome (GHIS) [abstract P2-356. 85th Annual Meeting of the Endocrine Society, Chevy Chase, Md. The Endocrine Society; June 2003; Philadelphia, Pennsylvania; 2003
98. Barr WH, Garnett WR, Chinchilli VM, et al. Pharmacokinets of single dose subcutaneous administration of rhIGF-I/ rhIGFBP-3 in healthy adult volunteers [abstract #P1-191. Endocr Soc 88th Ann Meeting; Boston Mass. 2006. 209
99. Camacho-Hübner C, Rose S, Preece MA, et al. Pharmacokinetic studies of recombinant human insulinlike growth factor I rhIGF-I/rhIGFbinding protein-3 complex administered to patients with growth hormone insensitivity syndrome. J Clin Endocrnol Metab 2006;91:1246-52
100. Savage M, Underwood L, Yordam N, et al. Treatment of short stature in children with severe primary IGF-I deficiency with once daily rhIGF-I/ rhIGFBP-3 administration [abstract # CF1-100. Europ Soc Paed Soc, 45th Ann Meeting Rotterdam. Horm Res 2006;65(Suppl 4):30
101. Tonella P, Flück CE, Mullis PE. Insulin-like growth factor-I treatment in primary growth hormone insensitivity: Effect of recombinant human IGF-I (rhIGF-I) and rhIGF-I/rhIGF-binding protein-3 complex. Horm Res Paediatr 2010;73:140-7
102. Besson A, Salemi S, Eble A, et al. Primary GH insensitivity (Laron's syndrome) caused by a novel 4kb deletion encompassing exon 5 of the GH receptor gene: Effect of intermittent longterm treatment with recombinant human IGF-I. Eur J Endocrinol 2004;150:635-42 (Pubitemid 38786532
103. Ekstrom K, Carlsson-Skwirut C, Ritzén EM, et al. Insulin-Like growth factor-I and insulin-like growth factor binding protein-3 cotreatment versus insulin-like growth factor-1 alone in two brothers with growth hormone insensitivity syndrome: Effects on insulin sensitivity, body composition and linear growth. Horm Res Paediatr 2011;76:355-66
104. Enberg B, Luthman H, Segnestam K, et al. Characterisation of novel missense mutations in the GH receptor gene causing severe growth retardation. Eur J Endocrinol 2000;143:71-6 (Pubitemid 30482202
105. Saukkonen T, Amin R, Williams RM, et al. Dose-dependent effects of recombinant human insulin-like growth factor (IGF)-I/IGF binding protein-3 complex on overnight growth hormone secretion and insulin sensitivity in type 1 diabetes. J Clin Endocrinol Metab 2004;89:4634-41 (Pubitemid 39244481
106. Williams RM, McDonald A, O'Savage M, et al. Mecasermin rinfabate: RhIGF-I/rhIGFBP-3 complex: IPLEXTM. Expert Opin Metab Toxicol 2008;4:311-24 (Pubitemid 351618777
107. EI Kholy M, Elsedfy HH. Effect of GnRH analogue on height potential in patients with severe growth hormone insensitivity syndrome treated with IGF-I. J Pediatr Endocrinol Metab 2011;24:983-98
108. Guevara-Aguirre J, Rosenbloom AL, Guevara-Aguirre M, et al. Recommended IGF-I dosage causes greater fat accumulation and osseous maturation than lower dosage and may compromise long-Term growth effects. J Clin Endocrinol Metab 2013;98(2):839-45
109. Laron Z, Ginsberg S, Webb M. Nonalcoholic fatty liver in patients with Laron syndrome and GH gene deletion -preliminary report. Growth Horm IGF Res 2008;18:434-8 (Pubitemid 351944037
110. Bisker-Kassif O, Kauli R, Lilos P. Biphasic response of subscapular skinfold thickness to hGH or IGF-1 administration to patients with congenital IGHD, congenital MPHD and Laron syndrome. Obes Res Clin Pract 2012, doi.org/10.106/j.orcp. 2012.11.001
111. Ginsberg S, Laron Z, Arbiv Bed M, et al. The obesity of patients with Laron syndrome is not associated with excessive nutritional intake. Obesity Res Clin Pract 2009;3:3-8
112. Kornreich L, Horev G, Schwarz M, et al. Craniofacial and brain abnormalities in Laron syndrome (primary growth hormone insensitivity). Eur J Endocrinol 2002;146:499-503 (Pubitemid 34436461
113. Dagan Y, Abadi J, Lifschitz A, et al. Severe obstructive sleep apnoea syndrome in an adult patient with Laron syndrome. Growth Horm IGF Res 2001;11:247-9 (Pubitemid 33072265
114. Laron Z, Silbergeld A, Klinger B. Hyperandrogenism induced by insulinlike growth factor-I (IGF-I) treatment of two girls with Laron Syndrome. Hosp Q 1998;10:75-9 (Pubitemid 29063753
115. Klinger B, Anin S, Silbergeld A, et al. Development of hyperandrogenism during treatment with insulin-like growth factor-I (IGF-I) in female patients with Laron syndrome. Clin Endocrinol (Oxf) 1998;48:81-7
116. Galatzer A, Aran O, Nagelberg N, et al. Cognitive and psychosocial functioning of young adults with Laron syndrome. In: Laron Z, Parks JS, editors. Lessons from Laron syndrome (LS) 1966-1992. Pediatric and adolescent endocrinology, Karger, Basel New York; 1993. p. 24:53-60
117. Laron Z, Avitzur Y, Klinger B. Carbohydrate metabolism in primary growth hormone resistance (Laron syndrome) before and during insulin-like growth factor-I treatment. Metabolism 1995;44(4):113-18
118. Agladioglu SY, Cetinkaya S, Erdeve SS, et al. Diabetes mellitus with Laron syndrome: CXase report. J Pediatr Endocrinol Metab 2013;26(9-10):955-8
119. Laron Z, Weinberger D. Diabetic retinopathy in two patients with congenital IGF-I deficiency (Laron syndrome). Eur J Endocrinol 2004;151:103-6 (Pubitemid 39117370
120. Laron Z, Kauli R, Rosenzweig E. Sleep and sleep disorders in patients with Laron syndrome. In: Laron Z, Kopchick JJ, editors. Laron syndromefrom man to mouse. Springer, Heidelberg, New York; 2011. p. 317-20
121. Ben-Dov I, Gaides M, Scheinowitz M, et al. Reduced exercise capacity in untreated adults with primary growth hormone resistance (Laron syndrome). Clin Endocrinol (Oxf) 2003;59:763-7 (Pubitemid 37491581
122. Laron Z, Kauli R. Orthopedic problems in Laron syndrome. In: Laron Z, Kopchick JJ, editors. Laron syndromefrom man to mouse. Springer, Heidelberg, New York; 2011. p. 323-33
123. Kornreich L, Horev G, Schwarz M, et al. Laron syndrome abnormalities: Spinal stenosis, os odontoideum, degenerative changes of the atlanto-odontoid joint, and a small oropharynx. Am J Neuroradiol 2002;23:625-31 (Pubitemid 34411920
124. Hellstrom A, Carlsson B, Niklasson A, et al. IGF-I is critical for normal vascularization of the human retina. J Clin Endocrinol Metab 2002;87:3413-16 (Pubitemid 34816398
125. Bourla D, Laron Z, Snir M, et al. Insulin-like growth factor I affects ocular development: A study of untreated and treated patients with Laron syndrome. Ophtalmology 2006;113:1197-200
126. Zhao X, Donovan M. Combined growth hormone (GH) and insulin-like growth factor-I (IGF-I) treatment is more effective than GH or IGF-I alone at enhancing recovery from neonatal malnutrition in rats. J Nutr 1995;125:2773-86
127. Barner C, Petersson M, Engstrom BE, et al. Effects on insulin sensitivity and body composition of combination therapy with GH and IGF-I in GH deficient adults with type 2 diabetes. Europ J Endocrinol 2012;167:697-703
128. Holloway L, Butterfield G, Hintz RL, et al. Effects of recombinant human growth hormone on metabolic indices, body composition, and bone turnover in healthy elderly women. J Clin Endocrinol Metab 1994;79:470-9 (Pubitemid 24256538
129. Molitch ME, Clemmons DR, Malozowski S, et al. Evaluation and treatment of adult growth hormone deficiency: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2011;96:1587-609
130. Sondergaard E, Klose M, Hansen M, et al. Pegylated long-Acting human growth hormone possesses a promising once-weekly treatment profile, and multiple dosing is well tolerated in adult patients with growth hormone deficiency. J Clin Endocrinol Metab 2011;96(3):681-8
131. Luca G, Calvitti M, Mancuso F, et al. Reversal of experimental Laron syndrome by xenotransplantation of microencapsulated porcine Sertoli cells. J Control Release 2013;165:75-81
132. Laron Z, Klinger B. Are patients with Laron syndrome candidates for limb lengthening?. In: Laron Z, Mastragastino S, Romano C, editors. Limb lengthening for whom, when and how. Freund Publ House, London; 1995. p. 79-91
133. Benbassat CA, Eshed V, Kamjin M, et al. Are adult patients with Laron syndrome osteopenic?. A comparison between Dual-energy X-ray absorptiometry and volumetric bone densities. J Clin Endocrinol Metab 2003;88(10):4586-9 (Pubitemid 37357497
134. Shevah O, Laron Z. Patients with congenital deficiency of IGF-I seem protected from the development of malignancies: A preliminary report. Growth Horm IGF Res 2007;17:54-7
135. Steuerman R, Shevah O, Laron Z. Congenital IGF-I deficiency tends to confer protection against post-natal development of malignancies. Euro J Endocr 2011;164:485-9
136. Guevara-Aguirre J, Balasubramanian P, Guevara-Aguirre M, et al. Growth hormone receptor deficiency is associated with a major reduction in pro-Aging signaling, cancer and diabetes in humans. Sci Transl Med 2011;3(70):70ra13.